vs
BlueLinx Holdings Inc.（BXC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
BlueLinx Holdings Inc.的季度营收约是Royalty Pharma plc的1.2倍（$748.9M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 0.2%，领先34.2%），Royalty Pharma plc同比增速更快（4.8% vs 0.2%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.5%）
BlueLinx Holdings Inc.是美国经营建材与工业产品的批发分销商，总部位于佐治亚州亚特兰大，目前由Shyam Reddy担任公司总裁兼首席执行官，在美国本土相关分销领域开展业务
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
BXC vs RPRX — 直观对比
营收规模更大
BXC
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出4.6%
0.2%
净利率更高
RPRX
高出34.2%
0.2%
两年增速更快
RPRX
近两年复合增速
2.5%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $748.9M | $622.0M |
| 净利润 | $1.7M | $214.2M |
| 毛利率 | 14.4% | — |
| 营业利润率 | 1.3% | 62.4% |
| 净利率 | 0.2% | 34.4% |
| 营收同比 | 0.2% | 4.8% |
| 净利润同比 | -89.7% | 2.9% |
| 每股收益（稀释后） | $0.20 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXCRPRX
| Q4 25 | — | $622.0M | ||
| Q3 25 | $748.9M | $609.3M | ||
| Q2 25 | $780.1M | $578.7M | ||
| Q1 25 | $709.2M | $568.2M | ||
| Q4 24 | $710.6M | $593.6M | ||
| Q3 24 | $747.3M | $564.7M | ||
| Q2 24 | $768.4M | $537.3M | ||
| Q1 24 | $726.2M | $568.0M |
净利润BXCRPRX
| Q4 25 | — | $214.2M | ||
| Q3 25 | $1.7M | $288.2M | ||
| Q2 25 | $4.3M | $30.2M | ||
| Q1 25 | $2.8M | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $16.0M | $544.0M | ||
| Q2 24 | $14.3M | $102.0M | ||
| Q1 24 | $17.5M | $4.8M |
毛利率BXCRPRX
| Q4 25 | — | — | ||
| Q3 25 | 14.4% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | 15.7% | — | ||
| Q4 24 | 15.9% | — | ||
| Q3 24 | 16.8% | — | ||
| Q2 24 | 15.9% | — | ||
| Q1 24 | 17.6% | — |
营业利润率BXCRPRX
| Q4 25 | — | 62.4% | ||
| Q3 25 | 1.3% | 70.1% | ||
| Q2 25 | 1.9% | 36.3% | ||
| Q1 25 | 1.5% | 94.0% | ||
| Q4 24 | 1.7% | 60.9% | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.1% | 50.2% | ||
| Q1 24 | 3.8% | -13.0% |
净利率BXCRPRX
| Q4 25 | — | 34.4% | ||
| Q3 25 | 0.2% | 47.3% | ||
| Q2 25 | 0.6% | 5.2% | ||
| Q1 25 | 0.4% | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 2.1% | 96.3% | ||
| Q2 24 | 1.9% | 19.0% | ||
| Q1 24 | 2.4% | 0.8% |
每股收益（稀释后）BXCRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | $0.20 | $0.67 | ||
| Q2 25 | $0.54 | $0.07 | ||
| Q1 25 | $0.33 | $0.55 | ||
| Q4 24 | $0.67 | $0.46 | ||
| Q3 24 | $1.87 | $1.21 | ||
| Q2 24 | $1.65 | $0.23 | ||
| Q1 24 | $2.00 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.4M | $618.7M |
| 总债务越低越好 | $598.5M | $9.0B |
| 股东权益账面价值 | $623.0M | $9.7B |
| 总资产 | $1.6B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.96× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资BXCRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | $429.4M | $938.9M | ||
| Q2 25 | $386.8M | $631.9M | ||
| Q1 25 | $449.0M | $1.1B | ||
| Q4 24 | $505.6M | $929.0M | ||
| Q3 24 | $526.3M | $950.1M | ||
| Q2 24 | $491.4M | $1.8B | ||
| Q1 24 | $481.3M | $843.0M |
总债务BXCRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | $598.5M | $8.9B | ||
| Q2 25 | $596.4M | $8.0B | ||
| Q1 25 | $596.6M | $7.6B | ||
| Q4 24 | $575.1M | $7.6B | ||
| Q3 24 | $576.0M | $7.6B | ||
| Q2 24 | $574.6M | $7.6B | ||
| Q1 24 | $574.0M | $6.1B |
股东权益BXCRPRX
| Q4 25 | — | $9.7B | ||
| Q3 25 | $623.0M | $9.6B | ||
| Q2 25 | $621.3M | $9.5B | ||
| Q1 25 | $636.1M | $9.8B | ||
| Q4 24 | $646.4M | $10.3B | ||
| Q3 24 | $655.6M | $10.3B | ||
| Q2 24 | $652.3M | $9.8B | ||
| Q1 24 | $653.2M | $9.9B |
总资产BXCRPRX
| Q4 25 | — | $19.6B | ||
| Q3 25 | $1.6B | $19.3B | ||
| Q2 25 | $1.6B | $18.3B | ||
| Q1 25 | $1.6B | $17.6B | ||
| Q4 24 | $1.6B | $18.2B | ||
| Q3 24 | $1.6B | $18.0B | ||
| Q2 24 | $1.6B | $17.7B | ||
| Q1 24 | $1.6B | $16.1B |
负债/权益比BXCRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.96× | 0.93× | ||
| Q2 25 | 0.96× | 0.84× | ||
| Q1 25 | 0.94× | 0.78× | ||
| Q4 24 | 0.89× | 0.74× | ||
| Q3 24 | 0.88× | 0.74× | ||
| Q2 24 | 0.88× | 0.78× | ||
| Q1 24 | 0.88× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.6M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $52.7M | — |
| 自由现金流率自由现金流/营收 | 7.0% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 35.42× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-25.1M | — |
8季度趋势，按日历期对齐
经营现金流BXCRPRX
| Q4 25 | — | $827.1M | ||
| Q3 25 | $58.6M | $702.6M | ||
| Q2 25 | $-26.8M | $364.0M | ||
| Q1 25 | $-33.9M | $596.1M | ||
| Q4 24 | $18.7M | $742.5M | ||
| Q3 24 | $61.8M | $703.6M | ||
| Q2 24 | $35.8M | $658.2M | ||
| Q1 24 | $-31.1M | $664.6M |
自由现金流BXCRPRX
| Q4 25 | — | — | ||
| Q3 25 | $52.7M | — | ||
| Q2 25 | $-36.4M | — | ||
| Q1 25 | $-39.8M | — | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $29.3M | — | ||
| Q1 24 | $-36.6M | — |
自由现金流率BXCRPRX
| Q4 25 | — | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | -4.7% | — | ||
| Q1 25 | -5.6% | — | ||
| Q4 24 | -0.2% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | -5.0% | — |
资本支出强度BXCRPRX
| Q4 25 | — | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | 0.8% | — |
现金转化率BXCRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | 35.42× | 2.44× | ||
| Q2 25 | -6.21× | 12.06× | ||
| Q1 25 | -12.09× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 3.86× | 1.29× | ||
| Q2 24 | 2.50× | 6.45× | ||
| Q1 24 | -1.78× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXC
| Specialty Products | $525.5M | 70% |
| Structural Products | $223.4M | 30% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
